By Denis Katz, MD, MHA
Founder, Salience Clinical

Beyond the Chemistry Paradigm

For decades, major depressive disorder (MDD) has been framed as a disorder of neurotransmitters primarily serotonin, norepinephrine, and dopamine. This model enabled meaningful therapeutic progress, but its limits are increasingly clear.

A large proportion of patients do not achieve sustained remission. Treatment resistance remains common, and relapse rates are high even among responders. These realities suggest that incremental adjustments to synaptic signaling have reached a practical ceiling in their ability to reshape long-term outcomes.

The next transformation in neuropsychiatry will not be driven by chemistry alone.
It will be driven by architecture.

An Architectural Lens on Depression

By architecture, we refer to the structure and dynamics of large-scale brain networks how they connect, interact, and transition over time.

Over the past decade, advances in functional imaging, multimodal data integration, and computational neuroscience have converged on a consistent observation: depression is associated with dysregulation across three core networks:

• Salience Network (SN): Identifies and prioritizes relevant stimuli while coordinating transitions between other networks
• Central Executive / Frontoparietal Network (CEN/FPN): Governs attention, working memory, and goal-directed cognition
• Default Mode Network (DMN): Supports internal mentation, self-referential thought, and autobiographical processing

The critical variable is not simply activity within these systems, but their interaction. In MDD, this interaction becomes destabilized.

Common findings include:

• Reduced functional separation between DMN and executive systems
• Aberrant coupling between salience and both DMN and CEN
• Impaired switching, driven by salience network dysfunction

The result is a system biased toward persistent self-focus and insufficient cognitive control a state that reinforces rumination and behavioral inertia.

This reflects a breakdown in coordination, not just chemistry.

Why Signal Modulation Falls Short

Most current interventions operate at the level of signal intensity:

• Pharmacologic therapies alter neurotransmission
• Neuromodulation approaches influence regional excitability

However, few are explicitly designed to recalibrate relationships between networks how they balance, inhibit, and switch.

If executive systems remain under-engaged and default/salience systems remain dominant, symptom relief may occur without restoring underlying system dynamics. This creates a plausible pathway to relapse.

The strategic question becomes:

Can we design treatments that restore network balance and flexibility not just modulate activity?

Toward Network-Centric Intervention

A more advanced model of precision psychiatry is beginning to emerge one focused on system-level restoration:

• Connectivity-Guided Stratification
  Identifying patient subtypes based on network organization and predicting treatment response
• Network-Level Endpoints
  Measuring changes in connectivity, flexibility, and switching alongside traditional symptom scales
• Closed-Loop Neuromodulation
  Delivering stimulation based on real-time biomarkers and network state
• Plasticity-Enhancing Biologics
  Leveraging agents that reshape circuit dynamics in addition to synaptic strength
• Targeted Behavioral Interventions
  Designing digital and cognitive therapies that actively engage executive networks and reduce maladaptive internal focus

This is not a departure from neurochemistry it is its integration into a systems framework.
Neurotransmitters influence circuits. Circuits organize into networks. Networks define behavior.

Strategic Implications for CNS Innovation

1. Drug Development

Therapeutics should be assessed not only by symptom improvement, but by their ability to modify connectivity patterns across key networks. Early-phase trials should incorporate these measures prospectively to inform mechanism differentiation and dose selection.

2. Clinical Trial Design

Network-based biomarkers offer a path to:

• Reduced heterogeneity
• Improved patient selection
• Earlier detection of treatment response

Embedding these metrics into study design can significantly enhance signal detection and interpretability.

3. Medical Affairs Narrative

The chemical imbalance framework is increasingly outdated. A network-based model more accurately reflects current science and provides a stronger foundation for integrated therapeutic strategies spanning pharmacology, devices, and digital health.

4. Durability of Treatment Effect

Sustained remission may depend on restoring:

• Efficient network switching
• Appropriate salience assignment
• Robust executive engagement

Interventions that address these dimensions are more likely to produce lasting benefit.

Operationalizing Architecture

Consider a next-generation treatment-resistant depression program:

A rapid-acting agent is paired with connectivity-guided neuromodulation. Patients are selected based on baseline network signatures. Success is defined not only by symptom change, but by normalization of interactions across key brain networks.

This represents a shift from treating symptoms to restoring system function.

A Defining Moment for the Field

Several developments are converging:

• Network neuroscience has matured into actionable models
• Advanced analytics can extract predictive patterns from complex brain data
• Neuromodulation platforms are becoming increasingly precise and programmable
• Multimodal datasets enable biologically grounded stratification

Organizations that integrate these capabilities into their development strategy will define the next decade of CNS therapeutics.

Those that remain anchored in a purely chemical paradigm will face diminishing returns.

The Salience Clinical Perspective

Salience Clinical focuses on translating systems neuroscience into executable development strategy. Our work integrates network biology, biomarker design, clinical trial architecture, and regulatory positioning.

The goal is not theoretical insight but practical advantage.
Turning emerging science into decisions that improve probability of success.